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Seminarscalled Tregs, are a subpopulation of CD4þ T cells specialized for immune suppression. Tregs
contribute to maintenance of peripheral immune tolerance, and their defects are thought to
play a role in the pathogenesis of various autoimmune diseases. Immune thrombocytopenia
(ITP) is an autoimmune disease characterized by increased platelet destruction and reduced
platelet production, resulting in decreased platelet count. Recently, a series of studies in adults
and children with ITP have found that the frequency of Tregs is reduced in circulation, bone
marrow, and spleen, and Treg function is impaired. Treg dysregulation is improved after
platelet count is recovered by treatment with dexamethasone, rituximab, or thrombopoietin
receptor agonists. In addition, a critical role of Tregs in preventing the anti-platelet auto-
immune response has been demonstrated in mice deficient in functional Tregs. Thrombocy-
topenia observed in Treg-deficient mice is mediated through production of IgG anti-platelet
autoantibodies, which is analogous to human ITP. Further studies evaluating mechanisms of
Treg dysregulation in ITP patients are necessary to elucidate the pathogenesis of ITP and
develop novel therapeutic strategies that suppress anti-platelet autoimmune response.
Semin Hematol 50:S43–S49. C 2013 Published by Elsevier Inc.Open access under CC BY-NC-ND license.I
mmune thrombocytopenia (ITP) is an autoim-
mune bleeding disorder in association with
increased platelet destruction and impaired pla-
telet production, both of which are mediated by IgG
anti-platelet autoantibodies.1 The major autoanti-
body targets are platelet membrane glycoproteins
(GPs), such as GPIIb/IIIa and GPIb/IX.2 It is widely
appreciated that production of IgG autoantibodies
requires activation of autoantigen-specific CD4þ T
cells. In fact, in ITP patients, we have identified
CD4þ T cells reactive to GPIIb/IIIa, which are able to
stimulate B cells to produce IgG antibodies that bind
normal platelet surfaces.3 Based on detailed analyses
of GPIIb/IIIa-reactive CD4þ T cells and B cells in ITP
patients, we have proposed a ‘‘pathogenic loop’’
model for the ongoing IgG anti-platelet autoantibodyblished by Elsevier Inc.
i.org/10.1053/j.seminhematol.2013.03.018
of this article was supported by the International Coop-
P Study Group (ICIS).
f interest: The authors have no conflicts of interest to
f Rheumatology, Department of Internal Medicine, Keio
y School of Medicine, Tokyo, Japan.
rrespondence to Masataka Kuwana, MD, PhD, Division of
ology, Department of Internal Medicine, Keio University
of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo
, Japan. E-mail: kuwanam@z5.keio.jp
in Hematology, Vol 50, No 1, Suppl 1, January 2013, p
Open access under CC BY-NC-ND license.response in ITP patients (Figure 1).4 Specifically,
macrophages in the reticuloendothelial system cap-
ture opsonized platelets via Fcg receptors, and
present antigenic platelet GP-derived peptides to T
cells. Autoreactive CD4þ T cells are then activated
by recognition of the antigenic peptides and exert
helper activity to stimulate B cells to produce IgG
anti-platelet autoantibodies, which in turn bind to
circulating platelets. Theoretically, once this patho-
genic loop is established, production of IgG anti-
platelet autoantibodies goes on endlessly.
It is likely that the immune system is repeatedly
exposed to foreign proteins that cross-react with
autoantigens. In this regard, onset of ITP often
precedes virus infection or immunization, especially
in children. In addition, IgG anti-GPIIb/IIIa antibod-
ies in patients with human immunodeficiency virus
(HIV)-related ITP cross-react with HIV-associated
gp120.5 These potentially cross-reactive foreign anti-
gens may trigger the pathogenic loop, resulting in
continuous production of IgG anti-platelet autoanti-
bodies. Thus, immune regulatory mechanisms
should play a critical role in preventing potential
harmful autoimmune response to circulating plate-
lets. One of the immune regulatory mechanisms
involved in the pathogenic process of ITP is an
inhibitory Fcg receptor FcgRIIB expressed on
reticuloendothelial macrophages. Namely, plateletp S43–S49 S43
Figure 1. Schematic representation of a continuous pathogenic loop carried out by macrophages in the reticuloen-
dothelial system, autoreactive CD4þ T cells, and antibody-producing B cells that maintains anti-platelet autoantibody
production in ITP patients. Tregs suppress an interaction between antigen-captured macrophages and autoreactive CD4þ
T cells, resulting in prevention from a drive of the pathogenic loop.
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of Helicobacter pylori is mediated through a change
in Fcg receptor balance toward the inhibitory
FcgRIIB.6 Another potential immune regulatory
mechanism includes maintenance of immune toler-
ance and homeostasis in periphery by CD4þ regu-
latory T cells.7 Of various CD4þ regulatory T cell
subsets, CD4þ T cells with high expression of CD25
and expression of transcription factor forkhead box
P3 (Foxp3), called Foxp3 Tregs or just simply called
Tregs, have recently been examined for their poten-
tial association with pathophysiology of ITP. In this
review, we summarize updated knowledge of roles
of Tregs in the pathogenic process of ITP.Figure 2. Distinct subsets of CD4þ regulatory T cells.
Tr1, type 1 regulatory T cells; and Th3, T helper 3 cells.CD4þ REGULATORY T-CELL SUBSETS
CD4þ Tregs directly suppress acquired immune
responses in periphery and are essential regulators
of self-tolerance.7 They are a heterogeneous cell
population with distinct surface phenotypes, cyto-
kine production profiles, and mechanisms of
immune suppression. Figure 2 summarizes well-
characterized subsets of CD4þ Tregs. Historically,Sakaguchi and colleagues reported an intriguing
finding that neonatal thymectomy 3 days after birth
in mice resulted in autoimmune damage of various
organs, such as thyroid gland, stomach, ovary, and
testis, with appearance of tissue-specific
Role of Tregs in the pathophysiology of ITP S45autoantibodies in circulation.8 This led to discovery
of autoimmune suppressive T cells, which were
produced in the thymus and delivered to the periph-
ery. This regulatory T-cell subset with expression of
CD25 and FoxP3 is currently called naturally occur-
ring Tregs. On the other hand, CD4þ T cells that
acquire regulatory properties under particular con-
ditions in periphery are called adaptive Tregs, which
include type 1 Tregs (Tr1) that produce a high level
of interleukin (IL)-10,9 and T helper 3 cells (Th3)
that produce transforming growth factor-b (TGF-
b).10 Interestingly, CD4þ Tregs with identical phe-
notype to naturally occurring Tregs can be generated
by antigenic stimulation of naive CD4þ T cells in the
presence of TGF-b and IL-2.11–14 This adaptive
regulatory T-cell subset is called induced Tregs. We
focus on CD4þCD25þFoxP3þ Tregs, which include
both naturally occurring and induced Tregs, in this
review.
Mechanisms of immune suppression by Tregs are
not fully elucidated, but several distinct mechanisms
are proposed to date.15,16 First, Tregs secrete immu-
nosuppressive cytokines, such as TGF-b, IL-10, and
IL-35. Second, Tregs exert direct cytotoxicity to
activated effector T cells through secretion of per-
forin and granzyme A. Third, Tregs inactivate effec-
tor T cells via cell surface immunosuppressive
molecules, such as cytotoxic T lymphocyte antigen
4 (CTLA4) and Fas ligand. Moreover, CTLA4
expressed on Tregs modulates functions of special-
ized antigen-presenting cells, such as dendritic cells,
through binding to CD80/CD86, resulting in inhib-
ition of maturation, downregulation of CD80/CD86,
and induction of immunoregulatory enzyme indole-
amine-2,3-desoxygenase. Finally, Tregs compete
with effector CD4þ T cells for interaction with
antigen-captured antigen-presenting cells.TREGS AND AUTOIMMUNE DISEASES
The negative selection process in the thymus
deletes T cells reactive to autoantigens expressed
by thymic epithelial cells, and plays a critical role in
maintenance of the central immune tolerance. On
the other hand, autoreactive T cells that escape from
apoptosis during the negative selection process are
delivered to periphery. These potentially harmful
autoreactive T cells are suppressed or deleted in
periphery through Treg-mediated mechanisms.15 If
this were true, impairment of Treg-mediated
immune regulation would lead to development of
autoimmune diseases. In fact, mice and humans with
genetic mutations in the Foxp3 gene, which lack
functional Tregs, represent severe inflammation and
autoimmunity, indicating importance of Tregs in
preventing harmful autoimmune response.17 In addi-
tion, reduced number of Tregs and defect in Tregfunction have been reported in patients with various
autoimmune diseases, including type 1 diabetes,
multiple sclerosis, and systemic lupus erythemato-
sus.18 Interestingly, gene polymorphisms within the
CTLA4 locus have been identified as the disease
susceptibility gene for many autoimmune diseases,
including type 1 diabetes, myasthenia gravis, sys-
temic lupus erythematosus, and rheumatoid
arthritis.19DYSREGULATED TREGS IN ITP PATIENTS
Given a critical role of Tregs in preventing the
autoimmune response, dysregulation of Tregs could
also be associated with pathophysiology of ITP.
Since 2007, many investigator groups examined
frequency and function of Tregs in patients with
ITP (Table 1).20–31 The majority of studies demon-
strated a decreased frequency of Tregs in peripheral
blood CD4þ T cells in ITP patients, compared with
healthy controls. The lowest Treg frequency was
detected in patients with acute phase of the disease
and/or with low platelet count, and Tregs were
increased in remission. Treg deficiency was reported
in both adults and children with ITP. One study in
children found that severe reduction of Tregs was
associated with prolonged thrombocytopenia, while
mild reduction was associated with brief duration,
suggesting that Treg proportion may be a prognostic
marker.30 Some studies failed to detect differences
in Treg frequencies between ITP patients and
healthy controls. These inconsistent results may be
explained by use of different phenotypes for identi-
fication of Tregs (CD4þCD25þ, CD4þFoxp3þ,
CD4þCD25highFoxp3þ, CD4þCD25bright, and
CD4þCD25þCD127low). For example, three studies
that used CD4þCD25highFoxp3þ cells to define Tregs
failed to detect difference in the Treg frequency in
peripheral blood from ITP patients and healthy
controls.24,26,29 Interestingly, cells with this pheno-
type abundantly contain naturally occurring Tregs,
suggesting that quantitative alternation occurs pri-
marily within induced Tregs, rather than naturally
occurring Tregs. It is imperative to take account of
definitions of Tregs upon interpretation of the
results in individual studies. On the other hand,
Treg’s ability to suppress allogeneic T-cell response
was assessed by a co-culture assay consisting of
sorted Tregs and allogeneic effector CD4þ T cells.
In all studies evaluating Treg function, their immu-
nosuppressive function was inferior in ITP patients
than in controls.21,23,24,26
Treg frequency was also decreased in bone mar-
row and spleen from patients with ITP.25,29 A recent
histologic analysis of spleen from ITP patients iden-
tified two different splenic structures accommodat-
ing proliferating B cells; germinal center and
Table 1. Frequency and Function of Tregs in Periphery From ITP Patients
Subjects
of ITP
Method for
Identification
of Tregs Treg Frequency* Treg Function*
Therapeutic
Responses of Treg
Frequency and
Function
Sakakura M
et al20
Adults CD4þCD25þ
(FCM)
Decreased in PB NT NT
Liu B et al21 Adults CD4þCD25þ
(FCM)
Decreased in PB Defective in PB NT
Ling Y et al22 Adults CD4þFoxp3þ
(FCM)
Decreased in PB NT Restored frequency
with high-dose
dexamethasone
Stasi R et al23 Adults CD4þFoxp3þ
(FCM)
Decreased in PB Defective in PB Restored frequency and
function with RTX
Yu J et al24 Adults CD4þCD25high-
Foxp3þ (FCM)
Unchanged in PB Defective in PB NT
Olsson B et al25 Adults CD4þCD25bright
(FCM)
Unchanged in PB
Decreased in
BM
NT NT
Bao W et al26 Adults CD4þCD25high-
Foxp3þ (FCM)
Unchanged in PB Defective in PB Restored function with
thrombopoietic
agents
Li Z et al27 Adults CD4þCD25þC-
D127low
(FCM)
Decreased in PB NT Restored frequency
with RTX plus
glucocorticoids
Aboul-Fotoh
Lel-M et al28
Children CD4þCD25high
(FCM)
Decreased in PB NT NT
Audia S et al29 Adults CD4þCD25high-
Foxp3þ (FCM)
Unchanged in PB
Decreased in
spleen
NT Unchanged frequency
with RTX
Zahran AM
et al30
Children CD4þCD25high-
Foxp3þ (FCM)
Decreased in PB NT NT
Daridon C et al31 Adults Foxp3þ (IHC) Decreased within
GC PLN of
spleen
NT NT
*Compared with healthy or non-ITP controls.
Abbreviations: ITP, immune thrombocytopenia; FCM, flow cytometry; IHC, immunohistochemistry; PB, peripheral blood; BM, bone
marrow; GC, germinal centers; PLN, proliferative lymphoid nodules; NT, not tested; RTX, rituximab.
T. Nishimoto and M. KuwanaS46proliferative lymphoid nodule.31 Foxp3þ Tregs were
reduced within these two structures, suggesting
involvement of Treg deficiency in activation of
autoantibody-producing B cells. Taken together, in
ITP patients, Treg deficiency is found in circulation
as well as in the secondary lymphoid organs.
Several studies evaluated serial changes of Treg
frequency and function before and after treatment.
High-dose dexamethasone and rituximab increased
proportion of Tregs in responders,22,23,27 although
one study failed to confirm an increase of Treg
frequency after rituximab treatment.29 On the other
hand, thrombopoietin receptor agonists failed to
increase Treg frequency, but improved Tregfunction.26 Plasma levels of TGF-b, which is required
for development of induced Tregs, were increased
after treatment with thrombopoietin receptor
agonists.ROLES OF TREGS IN PATHOPHYSIOLOGY
OF ITP
To investigate Tregs’ role in preventing ITP, we
examined whether Treg deficiency induced ITP
in mice. Treg-deficient mice were generated by trans-
ferring Treg-depleted CD4þCD25 T cells isolated
from BALB/c splenocytes into syngeneic nude mice
(Figure 3).32 Three weeks after transfer, some mice
Figure 3. Autoantibody-mediated immune thrombocy-
topenia in Treg-deficient mice. (A) Treg-deficient mice
were generated by adoptive transfer of Treg-depleted
CD4þ T cells isolated from BALB/c mice into syngeneic
nude mice. Some Treg-deficient mice developed bruises
in association with a low platelet count (inset). (B) Serial
platelet counts in Treg-deficient mice with and without
thrombocytopenia. *Po.01.
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low platelet count. When the number of Treg-deficient
mice was increased, we confirmed that approximately
one third of them developed chronic thrombocytope-
nia, which sustained for at least 12 weeks. IgG anti-
bodies capable of binding to intact platelets were
exclusively detected in platelet eluates and in super-
natants of unstimulated splenocyte cultures from
thrombocytopenic mice. These findings suggest that
thrombocytopenia observed in Treg-deficient mice is
mediated through production of IgG anti-platelet auto-
antibodies, which is analogous to human ITP. Further-
more, Treg-deficient mouse is a novel animal model for
ITP, especially reflecting induction and propagation of
the autoimmune response to platelets.
To confirm the theory that Treg deficiency was
responsible for the onset of ITP, CD4þCD25þ Tregs
were transferred together with Treg-depleted CD4þ T
cells. As expected, simultaneous transfer of Tregs
completely prevented the onset of ITP, while adoptive
Treg transfer after onset of ITP had no effect on
platelet count, suggesting a primary role of Tregs in
induction phase rather than maintenance phase of
the autoimmune response. We further examinedmechanisms responsible for Tregs’ effects on suppres-
sion of the ITP onset, focusing on CTLA4. Treatment
with anti-CTLA4 blocking antibody cancelled the
Treg’s protective effect against ITP, but treatment with
control antibodies had no effect. Taken together,
results obtained from our Treg-deficient ITP model
indicate that Tregs play a critical role in preventing
anti-platelet autoimmune response by engaging
CTLA4.
Recently, mechanisms for peripheral Treg defi-
ciency were investigated using another mouse model
for ITP. In this model, GPIIIa knockout mice were
immunized with wild-type platelets, and their spleno-
cytes were transferred into severe combined immu-
nodeficiency mice. This treatment resulted in onset of
thrombocytopenia, production of IgG anti-platelet
antibodies, and induction of platelet-reactive cyto-
toxic T cells.33 Interestingly, in this ITP model, Tregs
in the thymus were markedly increased, but Tregs in
the spleen were decreased, compared with control
mice.34 Treatment with intravenous immunoglobulin
raised the platelet count, and normalized the Treg
distribution in the thymus and spleen. These results
propose an intriguing theory that peripheral Treg
deficiency is caused by thymic retention.CONCLUSIONS AND FURTHER PROSPECTS
Recent studies in patients with ITP and in mouse
models mimicking ITP have clearly shown that Tregs
play an essential role in preventing from a drive of a
‘‘pathogenic loop’’ model for the pathophysiology of
ITP (Figure 1). Treg impairment allows autoimmune
effector mechanisms to elicit ITP, upon exposure to
the trigger known to induce ITP, such as infection of
certain microorganisms. Further studies evaluating
mechanisms for Treg dysregulation in ITP patients
are necessary to elucidate the induction phase of
pathogenesis of ITP. On the other hand, two recent
studies have shown that low-dose IL-2 therapy leads
to recovery and activation of Tregs and subsequent
clinical improvement in patients with chronic graft-
versus-host disease or in those with vasculitis related
to hepatitis C virus infection.35,36 Although adoptive
transfer of Tregs after onset of the disease is shown
to be inefficient in various autoimmune mouse
models, low-dose IL-2 therapy is a promising
approach to develop a novel therapeutic strategy
for autoimmune diseases, including ITP.Acknowledgments
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